---

title: "Evidence of clinical and brain recovery in post-COVID-19 condition: a three-year follow-up study"
tags:
- ðŸ§ª Biomarker
created: '2025-09-23'
published: '2025-09-23'

---


<details>
<summary>Dadsena et al. (2025)</summary>

- **Authors:** Ravi Dadsena, PhD; Sophie Wetz; Anna Hofmann, MD, PhD; Ana Sofia Costa, PhD; Sandro Romanzetti, PhD; Stella Andrea Lischewski, MD, PhD; Christina Krockauer, MD, PhD; Carolin Balloff, PhD; Ferdinand Binkofski, MD, PhD; JÃ¶rg B. Schulz, MD, PhD; Kathrin Reetz, MD, PhD; Julia Walders, MD.
- **Institutes:** Department of Neurology, RWTH Aachen University, Aachen, Germany; JARA Brain Institute Molecular Neuroscience and Neuroimaging (INM-11), Research Centre JÃ¼lich and RWTH Aachen University, Aachen, Germany; German Center for Neurodegenerative Diseases (DZNE), TÃ¼bingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University Hospital TÃ¼bingen, TÃ¼bingen, Germany; Institute for Neuroscience and Medicine (INM-4), Research Center JÃ¼lich GmbH, JÃ¼lich, Germany; Department of Neurology, Medical Faculty and University Hospital DÃ¼sseldorf, Heinrich Heine University, DÃ¼sseldorf, Germany; Department of Neurology, Kliniken Maria Hilf GmbH, MÃ¶nchengladbach, Germany.
- **Publisher:** Brain Communications
- **Link:** [DOI](https://doi.org/10.1093/braincomms/fcaf366)

</details>


## Summary

This research provides valuable long-term insight, showing that over three years, many Long COVID patients experience a gradual clinical improvement. The study's brain imaging results are particularly noteworthy: while some structural changes persist, the brain appears to be actively compensating, with some areas stabilizing and improving their connections (like the brainstem) while others work harder (like the basal ganglia). Crucially, the absence of elevated blood markers for neuronal damage or inflammation suggests that these brain changes are part of a recovery and reorganization process, rather than a progressive degenerative disease. This points to the brain's remarkable capacity for healing over the long term, even after a significant viral insult.

## What was researched?

This longitudinal study tracked the clinical symptoms, brain structure and function, and blood biomarkers of patients with Post-COVID-19 Condition (PCC) over a three-year period. The primary objective was to identify potential signs of brain recovery and understand the underlying factors associated with long-term changes after a SARS-CoV-2 infection.

## Why was it researched?

Previous studies have documented persistent fatigue, cognitive issues, and brain changes for up to two years after COVID-19. However, longer-term data was lacking, and most research had not integrated neuroimaging with analysis of inflammatory and neuronal injury markers. This study aimed to fill that gap by extending the observation period to three years to better understand the evolution of the condition and the trajectory of brain recovery.

## How was it researched?

This was a single-center, longitudinal observational study involving 51 patients with PCC and 23 healthy controls. Data was collected at three time points: approximately 6, 23, and 38 months after the initial infection. The methodology included structural and functional magnetic resonance imaging (MRI) to assess brain volume and activity, comprehensive neuropsychological testing for cognitive function, clinical questionnaires for symptoms like fatigue, and blood tests for markers of inflammation (interleukins) and neuronal injury (NfL, GFAP).

## What has been found?

Three years post-infection, patients showed slow but evident clinical improvement, with self-reported fatigue improving but still remaining moderate on average. Cognitive performance and muscle strength were largely normal. Brain imaging revealed an increase in the size of the ventricles (fluid-filled spaces in the brain) and a corresponding volume reduction in adjacent structures like the thalamus and basal ganglia. However, these same regions showed increased neuronal activation, while the brainstem, which had previously shown volume loss, stabilized and exhibited enhanced functional connectivity. Importantly, blood markers for neuronal injury and inflammation remained within normal ranges throughout the study.

## Discussion

The authors note that the observed volume loss in certain brain regions is not accompanied by biomarkers of neurodegeneration, suggesting it may be due to cellular shrinking rather than nerve cell death. They interpret the combination of structural changes with increased neuronal activation and connectivity as a sign of brain compensation and recovery. A key limitation is the absence of a control group that had asymptomatic COVID-19, as the study used pre-pandemic healthy control data for comparison.

## Conclusion & Future Work

The study concludes that patients with PCC demonstrate a slow but positive long-term recovery trajectory. This recovery is reflected in the brain through a pattern of structural stabilization (starting in the brainstem) and efficient neuronal compensation in other affected regions, all without evidence of ongoing systemic inflammation or neurodegeneration. The findings underscore a complex but ultimately hopeful path of recovery for many patients.
